ZION PHARMA
Zion is a leading drug discovery platform that develops "me-better" drugs that address true unmet needs.
ZION PHARMA
Industry:
Biotechnology
Founded:
2018-01-01
Address:
Shanghai, Shanghai, China
Country:
China
Website Url:
http://www.zionpharma.com
Total Employee:
11+
Status:
Active
Total Funding:
111.76 M USD
Technology used in webpage:
SPF SSL By Default Microsoft Exchange Online Office 365 Mail Microsoft Azure DNS ASP.NET Alibaba HiChina DNS Tengine Alibaba Cloud CDN
Similar Organizations
abillion
We're a passionate team unified by our mission to build the most engaged community for sustainability in the world.
Accellix
Accellix is an assay delivery platform
AccutarBio
AccutarBio employs artificial intelligence to revolutionize drug discovery.
BioIntervene
BioIntervene is engages in drug discovery and development.
Dizal Pharma
Dizal Pharma is a research-based biotechnology company.
Laekna Therapeutics
Laekna Therapeutics is a biotech company focusing on drug discovery and development.
Protai
Protai is an AI-powered drug discovery startup.
Qualie
Qualie is an unique research platform.
StoneWise
StoneWise is committed to establishing the world's leading intelligent drug discovery platform.
Zhaoke Ophthalmology Pharmaceutical
Zhaoke Ophthalmology Pharmaceutical is a Pharmaceutical platform.
Current Employees Featured
Founder
Investors List
Med-Fine Capital
Med-Fine Capital investment in Series B - Zion Pharma
Ming Bioventures
Ming Bioventures investment in Series B - Zion Pharma
Qiming Venture Partners
Qiming Venture Partners investment in Series B - Zion Pharma
Sherpa Healthcare Partners
Sherpa Healthcare Partners investment in Series B - Zion Pharma
OrbiMed
OrbiMed investment in Series B - Zion Pharma
Qiming Venture Partners
Qiming Venture Partners investment in Series B - Zion Pharma
Sherpa Healthcare Partners
Sherpa Healthcare Partners investment in Series A - Zion Pharma
Qiming Venture Partners
Qiming Venture Partners investment in Series A - Zion Pharma
Med-Fine Capital
Med-Fine Capital investment in Series A - Zion Pharma
Qiming Venture Partners
Qiming Venture Partners investment in Series A - Zion Pharma
Official Site Inspections
http://www.zionpharma.com
- Host name: catl.com
- IP address: 203.107.45.167
- Location: Hangzhou China
- Latitude: 30.294
- Longitude: 120.1619
- Timezone: Asia/Shanghai
More informations about "Zion Pharma"
赞荣医药
Zion Pharma Limited香港 是一家处于临床阶段，致力于小分子肿瘤创新药物研发的生物科技企业。 成立于2018年，在上海和苏州分别设立研发部门。 针对大量未满足的临床需求, 赞荣医药运用自己在DMPK方面的优势，设计和开发有差异 …See details»
Zion Pharma - Crunchbase Company Profile & Funding
Zion Pharma is a drug discovery platform. Headquarters Regions Asia-Pacific (APAC); Founded Date 2018; Founders Ding Zhou, Ziqiang Cheng; Operating Status Active; Last Funding Type …See details»
Zion Pharma 2025 Company Profile: Valuation, Funding …
Zion Pharma General Information Description. Developer of innovative small molecule drugs intended for oncology and tumor. The company is committed …See details»
Zion Pharma Ltd. - Drug pipelines, Patents, Clinical trials - Synapse
Www.zionpharma.com. Startups | Holding Company | 2018 | Hong Kong SAR, China | 10-50 | www.zionpharma.com. Last update 23 Jan 2025. Overview. Pipeline. Deal. Translational …See details»
Zion Pharma - Products, Competitors, Financials, Employees ...
Zionpharma.com. Overview & Products; Financials; Founded Year 2018. Stage Series B | Alive. Total Raised $71.9M. Last Raised $40M | 4 yrs ago. Mosaic Score. The Mosaic Score is an …See details»
Zion Pharma Ltd. (CN) - life-sciences-asia.com
Jan 1, 2018 Upcoming Events. Leerink Partners Global Healthcare Conference 2025 Miami; Barclays Global Healthcare Conference 2025 Miami; BioChina 2025 Suzhou; BIO-Europe …See details»
Zion Pharma - Portfolio Company Profile, Executives and Private …
See Zion Pharma's complete profile, including its private equity owner and the number of its executive contacts in our database. Zion Pharma is a private, clinical stage biotech company …See details»
Clinical Operation Director-苏州赞荣医药科技有限公司
Jul 20, 2021 简历接收邮箱： [email protected] （请在邮件主题中注明：姓名+意向职位） 联系电话：021-68906116. 公司官方网站：www.zionpharma.com. 公司地址： 上海：上海市浦 …See details»
Suzhou Zanrong Pharmaceutical Technology Co. Ltd.
了解Suzhou Zanrong Pharmaceutical Technology Co. Ltd. (苏州赞荣医药科技有限公司)公司的药物管线，治疗领域，技术平台，以及它的5项临床试验，疾病领域:肿瘤，技术平台:小分子化 …See details»
关于赞荣-苏州赞荣医药科技有限公司 - Zion Pharma
赞荣医药的历史可以用一句话来概括:“在人生的十字路口，选择创业的道路。”该公司联合创始人兼首席执行官程子强博士(Zack Cheng) 刚刚在大型制药公司DMPK完成了近20年的职业生涯， …See details»
Zion Pharma Ltd.. (5/9/23). "Press Release: Zion Pharma …
Additional information about Zion Pharma is available at www.zionpharma.com. Contacts For media and partnership inquiries: J. Michael French SVP, Corporate Development [email …See details»
Zion Pharma - VentureRadar
MtoZ Biolabs USA Privately Held MtoZ Biolabs is an international contract research organization (CRO) providing advanced proteomics, metabolomics, bioinformatics, and biopharmaceutical …See details»
Zion Pharma Ltd. (赞荣医药) - 药物管线_专利_临床试验_投融营收_ …
了解Zion Pharma Ltd. (赞荣医药)公司的药物管线，治疗领域，技术平台，以及它的10篇新闻，疾病领域:肿瘤，技术平台:小分子化药，药物:ZN-B-2262。See details»
ZION PHARMA - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for ZION PHARMA of Bengaluru, Karnataka. Get the latest business insights from Dun & Bradstreet.See details»
Zion Pharma Announces Global Agreement with Roche to Develop …
May 9, 2023 Additional information about Zion Pharma is available at www.zionpharma.com. Contacts For media and partnership inquiries: J. Michael French SVP, Corporate Development …See details»
药物发现-苏州赞荣医药科技有限公司 - Zion Pharma
利用对药物代谢和药代动力学(dmpk)的独特理解，赞荣医药有能力设计新型小分子抗肿瘤药物，克服传统药物化学的一些难点。See details»
Zion Pharma Signs an Agreement with Roche to Develop and …
Zion will receive ~$70M up front & additional fees upon achievement of near-term milestones, ~$610M in development, regulatory & sales-based milestonesSee details»
Zion Pharma Announces Global Agreement with Roche to Develop …
May 17, 2023 HONG KONG & SUZHOU, China & SHANGHAI--(BUSINESS WIRE)--Zion Pharma Limited, a Chinese biotechnology company focused on the development of brain …See details»
Roche grabs rights to Zion's brain-penetrant HER2 drug
May 9, 2023 Roche acquired global rights to Zion Pharma's experimental drug ZN-A-1041, an oral selective tyrosine kinase inhibitor targeting HER2 that is designed to cross the blood-brain …See details»
Zion Pharma Announces Global Agreement with Roche to Develop …
May 9, 2023 “Our agreement with Roche is the culmination of a tremendous team effort to deliver a potentially best-in-class therapy for patients with HER2-positive breast cancer, …See details»